Pancreatic cancer has long been one of the most lethal diagnoses in medicine, largely because it spreads early and hides from ...
GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of immune cell modulators for the treatment of inflammatory, fibrotic and autoimmune ...
A UCLA research team has identified the best design for a promising new type of immunotherapy that could be mass-produced to ...
Company reported $8.2 million in cash and cash equivalents at December 31, 2025 and raised additional $6.5 million in gross proceeds in January 2026 Balance sheet strengthened to fund operations into ...
A UCLA research team has identified the best design for a promising new type of immunotherapy that could be mass-produced to ...
Leading GMP cell therapy CDMO I Peace, Inc. ( specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, announced that it has successfully generated human induced ...
CytoMed Therapeutics (GDTC) issued a statement to address recent statements containing “inaccurate and misleading” claims ...
On January 28, 2026, GRI Bio reported additional positive data from its recently completed Phase 2a clinical trial of GRI-0621 in idiopathic pulmonary fibrosis, showing that RNA-sequencing gene ...
CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or the "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing ...